BrainsWay’s Stimulation Device Scores FDA Approval For Depression Settings
The FDA has granted 510(k) clearance to BrainsWay Ltd’s (NASDAQ:BWAY) Deep Transcranial Magnetic Stimulation (TMS) H7 Coil for its use in treating…
TRACON Pharmaceuticals Gets FDA Approval Of IND For CTLA-4 Antibody YH001 For Front-line Sarcoma Patients
SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its
Alnylam Reports Results From Phase 2 Study Of Investigational Cemdisiran For The Treatment Of IgA Nephropathy; Co Reports ‘Cemdisiran Was Generally Well-Tolerated in Patients with IgA Nephropathy’
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) today announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in development in
BrainsWay Receives New FDA Clearance For Treating Depression And Anxious Depression
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has
Novartis Scemblix Approved by the European Commission for Adult Patients with Chronic Myeloid Leukemia
Novartis today announced that the European Commission (EC) has approved Scemblix® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)1.Novartis today announced that the European Commission (EC) has approved Scemblix® (asciminib) for th
Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor…
Incyte Gets FDA Nod For Hematologic Malignancies Candidate
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.
Pfizer And BioNTech Complete Submission to European Medicines Agency For Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July
If authorized, both Omicron BA.1-adapted and Omicron BA.4/5-adapted bivalent vaccines will be available in the European
Inhibikase Shares Shoot Higher As FDA Announced Clearance To Blood-Cell Cancer Study
The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ (NASDAQ: IKT) Investigational New Drug (IND) application and issued a Study May Procced (SMP) letter for its drug candidate IkT-001Pro in the treatment of Chronic Myelogenous Leukemia (CML).
Sanofi Higher Dose Flu Vaccines Preferentially Recommended For Adults 65+ In CDC Morbidity And Mortality Weekly Report
This recommendation may help reduce the risk of the flu and flu-related complications in this high-risk population
Fluzone® High-Dose Quadrivalent (Influenza Vaccine) and